| P50 | author | Stephen S Whitehead | Q64866574 |
| | Brian R. Murphy | Q65658906 |
| | Anna Durbin | Q87882927 |
| | Joseph E Blaney | Q112131210 |
| | Bhavin Thumar | Q115158021 |
| P2093 | author name string | Michael T Rock | |
| | Brett A McKinney | |
| | Alexander C Schmidt | |
| | Peter F Wright | |
| | Susan Henderson | |
| | Mine R Ikizler | |
| | Sharon Ankrah | |
| P2860 | cites work | Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. | Q40382643 |
| | Dengue and yellow fever--challenges for the development and use of vaccines | Q40433390 |
| | rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. | Q40464785 |
| | The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. | Q40468552 |
| | Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. | Q40468558 |
| | rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers | Q40515729 |
| | Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity | Q40528042 |
| | Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine | Q40536052 |
| | Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates | Q40541513 |
| | Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells | Q40575878 |
| | A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. | Q40593111 |
| | Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. | Q40593118 |
| | Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers | Q40671401 |
| | A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans | Q40693060 |
| | Liver biochemical tests and dengue fever | Q40730168 |
| | Infections with two dengue viruses in Greece in the 20th century. Did dengue hemorrhagic fever occur in the 1928 epidemic? | Q40782627 |
| | Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation | Q40782907 |
| | Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells | Q40826105 |
| | Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers | Q40826955 |
| | Serological studies on volunteers inoculated experimentally with a dengue virus strain in 1943. | Q40831812 |
| | Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga | Q40875766 |
| | Measuring the burden of neglected tropical diseases: the global burden of disease framework | Q21144557 |
| | Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice | Q27469872 |
| | Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes | Q27472938 |
| | Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4 | Q27485404 |
| | Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity | Q27486434 |
| | Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity | Q27487377 |
| | Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity | Q27860703 |
| | A prospective study of dengue infections in Bangkok | Q28296365 |
| | Research on dengue during World War II | Q29619423 |
| | Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak | Q29619424 |
| | Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever | Q29619530 |
| | Prospects for a dengue virus vaccine | Q29619608 |
| | Global spread and persistence of dengue | Q29619711 |
| | A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996. | Q30778819 |
| | Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers | Q33336929 |
| | Epidemiology, clinical features, laboratory investigations and early diagnosis of dengue fever in adults: a descriptive study in Sri Lanka. | Q33368100 |
| | Antibody to dengue 1 detected more than 60 years after infection | Q34883085 |
| | Cytokine expression patterns associated with systemic adverse events following smallpox immunization | Q35106139 |
| | Development of a live attenuated dengue virus vaccine using reverse genetics | Q36428460 |
| | Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates | Q37423499 |
| | Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. | Q39417682 |
| | Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults | Q39955421 |
| | MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells | Q40209351 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| | Dengue virus | Q476209 |
| | phase I clinical trial | Q5452194 |
| P304 | page(s) | 834-41 | |
| P577 | publication date | 2009-11-01 | |
| P1433 | published in | American Journal of Tropical Medicine and Hygiene | Q15766943 |
| P1476 | title | Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers | |
| P478 | volume | 81 | |